Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) insider Julie Cooke sold 10,000 shares of the stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $140.19, for a total value of $1,401,900.00. Following the sale, the insider now directly owns 18,202 shares of the company’s stock, valued at approximately $2,551,738.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Neurocrine Biosciences Trading Down 1.9 %
NASDAQ:NBIX traded down $2.62 during mid-day trading on Tuesday, reaching $137.49. The company’s stock had a trading volume of 728,623 shares, compared to its average volume of 836,198. The firm’s fifty day moving average price is $137.42 and its two-hundred day moving average price is $136.06. The stock has a market cap of $13.84 billion, a P/E ratio of 37.88 and a beta of 0.37. Neurocrine Biosciences, Inc. has a 12-month low of $93.28 and a 12-month high of $148.37.
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) last issued its earnings results on Wednesday, May 1st. The company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.04 by ($0.62). The company had revenue of $515.30 million during the quarter, compared to analysts’ expectations of $512.21 million. Neurocrine Biosciences had a return on equity of 17.45% and a net margin of 18.65%. Analysts predict that Neurocrine Biosciences, Inc. will post 4.19 earnings per share for the current fiscal year.
Institutional Trading of Neurocrine Biosciences
Analysts Set New Price Targets
Several equities research analysts have weighed in on NBIX shares. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a research report on Wednesday, May 1st. Oppenheimer raised their target price on Neurocrine Biosciences from $200.00 to $216.00 and gave the stock an “outperform” rating in a research note on Thursday, May 2nd. JPMorgan Chase & Co. upped their price target on Neurocrine Biosciences from $148.00 to $158.00 and gave the company an “overweight” rating in a research report on Wednesday, March 20th. Wells Fargo & Company upgraded Neurocrine Biosciences from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $140.00 to $170.00 in a research report on Wednesday, April 24th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $152.00 price target on shares of Neurocrine Biosciences in a research note on Wednesday, May 29th. Six investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $152.00.
Check Out Our Latest Stock Analysis on Neurocrine Biosciences
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Featured Stories
- Five stocks we like better than Neurocrine Biosciences
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- RXO Shares Surge Following New Acquisition Deal
- How to Invest in Biotech Stocks
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- Investing in large cap stocks: Diving into big caps
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.